Inhibition of dengue virus infection by mannoside glycolipid conjugates by Schaeffer, Evelyne (Evelyne Schaeffer (e.schaeffer@ibmc-cnrs.unistra.fr)) (author) et al.
Contents lists available at ScienceDirect
Antiviral Research
journal homepage: www.elsevier.com/locate/antiviral
Inhibition of dengue virus infection by mannoside glycolipid conjugates
Evelyne Schaeﬀera, Vincent Flachera, Patrick Neubergb, Astrid Hostea, Adrien Bruleferta,
Jean-Daniel Faunya, Alain Wagnerb, Christopher G. Muellera,∗
a CNRS, Université de Strasbourg, Immunopathology and Therapeutic Chemistry, UPR 3572, 67000 Strasbourg, France
b CNRS, Université de Strasbourg, Laboratory of Functional Chemo Systems, UMR 7199, 67400 Illkirch, France
A R T I C L E I N F O
Keywords:
Dengue virus
Dendritic cells
Macrophages
Skin
Inhibitors
Cell membrane
A B S T R A C T
Dengue virus (DENV), a mosquito-borne ﬂavivirus, causes severe and potentially fatal symptoms in millions of
infected individuals each year. Although dengue fever represents a major global public health problem, the
vaccines or antiviral drugs proposed so far have not shown suﬃcient eﬃcacy and safety, calling for new antiviral
developments. Here we have shown that a mannoside glycolipid conjugate (MGC) bearing a trimannose head
with a saturated lipid chain inhibited DENV productive infection. It showed remarkable cell promiscuity, being
active in human skin dendritic cells, hepatoma cell lines and Vero cells, and was active against all four DENV
serotypes, with an IC50 in the low micromolar range. Time-of-addition experiments and structure-activity ana-
lyses revealed the importance of the lipid chain to interfere with an early viral infection step. This, together with
a correlation between antiviral activity and membrane polarization by the lipid moiety indicated that the in-
hibitor functions by blocking viral envelope fusion with the endosome membrane. These ﬁnding establish MGCs
as a novel class of antivirals against the DENV.
1. Introduction
Infection by Dengue virus (DENV) is a major cause of disease in
tropical and subtropical areas, with at least 100 million clinical cases
occurring each year, and more than 2.5 billion people at risk (Bhatt
et al., 2013; Stanaway et al., 2016). DENV is an arthropod-borne single-
stranded RNA virus of the Flavivirus genus, transmitted to humans by
infected Aedes mosquitoes. It comprises four related but antigenically
distinct serotypes, DENV-1, -2, -3, and -4. To restrict the burden on
public health, studies have concentrated on the elaboration of vaccines,
but the complex immunopathology of dengue has hampered their de-
velopment and eﬃcacy. No speciﬁc vaccine and no antiviral drug have
been licensed for clinical use; for review see (Julander et al., 2011; Lo
and Perng, 2016; Rather et al., 2017).
DENV cell-entry is mediated by a number of receptors (Kaufmann
and Rossmann, 2011) including the C-type lectins Dendritic Cell-Spe-
ciﬁc Intercellular adhesion molecule-3-Grabbing Nonintegrin (DC-
SIGN/CD209) (Navarro-Sanchez et al., 2003; Tassaneetrithep et al.,
2003) and the mannose receptor (MR/CD206) (Miller et al., 2008)
expressed by dendritic cells (DCs) and macrophages. Early in DENV
infection the ﬁrst events decisive for disease development are likely to
occur in the skin. It has been shown that after virus inoculation by the
mosquito, dermal DCs and macrophages are the primary targets of in-
fection (Cerny et al., 2014; Duyen et al., 2017; Ivory et al., 2015;
Schaeﬀer et al., 2015; Schmid et al., 2014).
In the search of DENV inhibitors, both viral and host proteins es-
sential for the viral replication cycle have been tested as potential
targets for antiviral development (see review, (Noble et al., 2010)). For
example, some strategies target viral RNA replication (Diamond et al.,
2002), the NS2B-NS3 protease (Chu et al., 2015), or the viral envelope
protein (Jadav et al., 2015), while others target cellular enzymes that
act as regulators of lipid homeostasis (Hyrina et al., 2017). The nu-
cleoside analogue balapiravir blocks viral RNA synthesis by acting as a
chain terminator. Chloroquine inhibits the fusion of the viral membrane
with that of the endosome, as well as virus maturation. Lovastatin in-
hibits virus entry, maturation and egress. Celgosivir impairs proper
glycosylation of the DENV E, prM and NS1 proteins. So far, no obvious
beneﬁcial clinical eﬀect was detected with any of these compounds
(Kaptein and Neyts, 2016). This emphasizes the need for continuous
research to ﬁnd new anti-DENV drugs.
Mannoside glycolipid conjugates (MGCs) are formed by three
building blocks: a tri-mannose head, a hydrophilic linker and a hy-
drophobic lipid chain. They are water-soluble and can self-assemble
into micelles. Our previous studies have shown that MGCs interact with
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lectin cell surface receptors that bind glycosylated molecules (Dehuyser
et al., 2012; Schaeﬀer et al., 2013). Because DENV is glycosylated on
the envelope protein, it appeared attractive to test the ability of MGCs
to inhibit DENV infection. Interestingly, MGCs also antagonize Toll-like
receptor type 4 signaling by lipopolysaccharide (LPS), although this
receptor or its co-receptor CD14 do not bind MGCs (Flacher et al.,
2015). This suggests that the biological properties of MGCs may not
only be mediated by a speciﬁc interaction with lectin receptors.
In this report, we have tested whether MGCs display antiviral ac-
tivity against DENV and have investigated the underlying mechanism.
We ﬁnd that a MGC, referred here as MGC 2, inhibits infection of pri-
mary human DCs, hepatoma and Vero cell lines. Using time-of-addition
experiments, we show data supporting the conclusion that an early
infection step is inhibited. Further, by visualization and quantitative
image analysis we provide supporting evidence that a disruption of
normal cell membrane composition may be the underlying mechanisms
of blockage of viral life cycle initiation.
2. Material and methods
2.1. Viruses, virus titration and cells
The pDENV-2 replicon of DENV-2 (strain 16681) was generously
provided by Dr. E. Harris (University of California, Berkeley, USA). The
clinical isolates DENV-1 (CRBIP 10.1), DENV-2 (RO7/2259), DENV-3
(CRBIP 10.3), and DENV-4 (VIMFH4) were a generous gift of Dr Anavaj
Sakuntabhai (Institut Pasteur, Paris, France). Viruses were produced in
C6/36 Aedes albopictus mosquito cells, as described (Schaeﬀer et al.,
2015). Titers in cell-free supernatants were determined by infection of
Vero cells as described (Lambeth et al., 2005). Infectivity titers were
expressed as FACS-infectious units (FIU)/ml.
African green monkey kidney Vero cells and human hepatoma
HepG2 cells were cultured at 37 °C in Dulbecco's modiﬁed Eagle's
medium (DMEM, Lonza) supplemented with 10% (v/v) heat-in-
activated fetal bovine serum (FBS) and gentamycin. Human monocytic
THP-1 and primary cells were cultured at 37 °C in RPMI 1640 supple-
mented with gentamycin and 10% (v/v) FBS (complete medium).
Human monocytes were puriﬁed from buﬀy coats by successive Ficoll
and Percoll gradients. Monocyte-derived dendritic cells (MDDCs) were
diﬀerentiated from monocytes by 5 days of culture with GM-CSF
(50 ng/ml, ImmunoTools) and IL-4 (10 ng/ml, ImmunoTools), as de-
scribed. Abdominal skin was obtained with written informed consent
and institutional review board approval, in agreement with the Helsinki
Declaration and French legislation. Dermal dendritic cells (dDCs) and
dermal macrophages were isolated from surgical explants of human
skin, as previously described (Schaeﬀer et al., 2015). Brieﬂy, dDCs were
allowed to migrate out of the skin for 2 days into a medium lacking or
containing IL-4. The non-migratory macrophages were isolated from
the tissue by enzymatic digestion. After culturing the dermal cell sus-
pension for 2 days, CD14+HLA-DR+ cells were puriﬁed by ﬂow cyto-
metric cell sorting (Schaeﬀer et al., 2015).
2.2. Compounds
Compounds MGC 2 and 2U were synthesized by the company
Roowin (Riom, France). Other MGCs were synthesized at the
Laboratory of Functional Chemo Systems (Illkirch, France). The
syntheses, physico-chemical properties and cytotoxicities of MGCs were
previously reported (Dehuyser et al., 2012; Flacher et al., 2015;
Schaeﬀer et al., 2013). All compounds were dissolved in water.
2.3. Cell cytotoxicity assay
The eﬀect of MGC 2 on cell viability was assessed by monitoring the
reduction by cellular deshydrogenases of the tetrazolium salt WST-1 to
dark yellow colored formazan, using the Cell Proliferation Reagent
WST-1 (Roche). Human cells (105 MDDCs, 5×104 dDCs, 2× 104
HepG2 cells) in 96-well culture plates were treated in quadruplicate
with diﬀerent concentrations of MGC 2, medium alone, or 1% Triton-
X100 at 37 °C. After 24 h, WST-1 stock solution diluted 10-fold in cell
culture medium (50 μL) was added at 37 °C. After 1 h (HepG2 cells) or
4 h (dDCs, MDDCs), the optical density of the resulting solutions was
measured at 450 nm using a microplate reader (Multiskan FC, Thermo
Scientiﬁc).
2.4. Antiviral assays
2.4.1. Inhibition assays
Assays were performed in 48-well plates. MDDCs (2× 105 cells) and
skin-puriﬁed cells (0.5× 105 cells) were preincubated with compounds
for 30min before exposure to DENV-2 (MOI of respectively 0.2 and
0.5). In time-of-addition assays, cells were treated with MGC 2 ac-
cording to the indicated timing. HepG2 cells (0.5× 105 cells) were
exposed to DENV-1, -2, -3, or -4 after 30min of pre-treatment with MGC
2. After incubation for 2 h at 37 °C in serum-free medium, cells were
washed and cultured in complete medium. After 2 days, cells infected
with DENV-2 were labeled for intracellular viral envelope protein with
mouse anti-dengue type 2 virus monoclonal antibody (clone 3H5.1,
Millipore MAB8702) and stained with APC rat anti-mouse IgG1 (BD
Biosciences). Cells infected with DENV-1, -2, -3, -4 were analyzed with
mouse anti-dengue complex monoclonal antibody (clone D3-2H2-9,
Millipore, MAB 8705) followed by APC rat anti-mouse IgG2a (BD
Biosciences). Fluorescence was measured by ﬂow cytometry
(FACSCalibur, Becton Dickinson) and the data analyzed using Cell
Quest Pro (BD Bioscience) or FlowJo (TreeStar).
2.4.2. Viral cell-entry by confocal microscopy
Cells were pre-treated in medium without serum with MGC 2
(100 μM) for 30min or left untreated, exposed to DENV-2 for 1 h, and
subjected or not to wash/chase by extensive washes and incubation in
complete medium for 1 h, before ﬁxation, permeabilization and la-
beling of DENV-E using Cy3-conjugated mAb 4G2 (kind gift from
Philippe Desprès, Institut Pasteur, Paris, France). Cells were labeled
with DiD (5 μg/ml, Thermo Fisher Scientiﬁc) for 10min at 37 °C. DAPI
was used as nuclear counterstaining. Slides were mounted using
Prolong Gold Antifade (Thermo Fisher Scientiﬁc). Images were ac-
quired on a Zeiss LSM 780 confocal microscope with GaAsP detector
and Zen acquisition software. Images were processed using the ImageJ
software and the DiD color was chosen in green.
2.5. Endosomal pH analysis
Vero cells (105) in 48-well plates were left untreated or treated with
NH4Cl (10mM), baﬁlomycin A1 from Streptomyces griseus (Sigma, 1 μM
ﬁnal) or MGC (10 and 100 μM) for 0.5 h or 3 h, as indicated. LysoSensor
Green DND-189 (Molecular Probes, 1 μM ﬁnal) was added for 4min at
37 °C before washes with PBS. Cells were detached with trypsin treat-
ment and analyzed by ﬂow cytometry.
2.6. Imaging ﬂow cytometry analysis
THP-1 (106) cells in 0.1 ml PBS were incubated with propidium
iodide (50 ng/ml) and the lipophilic probe dSQ12S (100 nM) (kind gift
of Dr Klymchenko, Université de Strasbourg, France) (Collot et al.,
2015) for 10min, before addition of MGCs (100 μM) for 10min. Amnis
ImageStreamX ﬂow cytometry analysis was performed (ImagoSeine
core facility of the Institut Jacques Monod, Paris, France). Cells were
imaged using Amnis ImageStreamX ﬂow cytometry (Zuba-Surma et al.,
2007) and live cells were selected as propidium iodide negative cells.
The cell images were analyzed by IDEAS software (Amnis) using the
Delta Centroid method to measure cell polarity (Zuba-Surma et al.,
2007).
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2.7. Statistical and data analysis
Graph-Pad Prism 6.01 was used for IC50 and CC50 determination by
nonlinear regression, and for statistical analysis using paired Student's
t-tests. Data were considered signiﬁcantly diﬀerent when p was less
than 0.05.
Fig. 1. Eﬀect of MGC 2 on DENV-2 infec-
tion of human skin DCs. (A) Structure of
MGC 2. (B) Representative FACS analysis of
mock- or DENV-infected dermal DCs pre-
incubated with IL-4 before addition of MGC
2 (100 μM) and the virus (MOI of 0.5). After
washing and culture for 2 days, DENV in-
fection of CD1c+ dDCs (HLA-DRHiCD14-)
and CD14+ dDCs (HLA-DR+CD14+) was
assessed as intracellular detection of DENV-
envelope (E) protein. The percentage in-
dicates the proportion of DENV-E+ cells.
The graphs depict the percentage of DENV-
E+ CD1c+dDCs (C) and DENV-E+
CD14+dDCs (D) as a function of MGC 2
concentrations in conditions with or
without IL-4. Each symbol represents a dif-
ferent skin donor. Mean values (± SD) are
shown as horizontal bars. (*: p < 0.1 **:
p < 0.01 ***: p < 0.001; ****:
p < 0.0001).
Table 1
Activities of MGC 2. IC50, half maximal DENV-2 inhibitory concentration;
CC50, 50% cytotoxic concentration; SI, Selectivity Index, calculated as CC50/
IC50. IC50 and CC50 values are means ± SD.
Cell type IC50 (μM) CC50 (μM) SI
Dermal DCs 1.4 ± 0.7 832 ± 83 594
MDDCs 1.0 ± 0.5 1544 ± 152 1544
HepG2 4.9 ± 1.9 1165 ± 165 238
Fig. 2. MGC 2 inhibits DENV-2 infection
of MDDCs. (A) Representative ﬂow cyto-
metry analysis of mock- or DENV-infected
MDDCs preincubated with MGC 2 (100 μM)
for 30min before exposure to the virus
(MOI of 0.2). The percentage of infection
was measured after 2 days as the in-
tracellular accumulation of DENV-E pro-
tein. (B) The graph depicts the percentage
of infection as a function of MGC 2 con-
centrations. (C) Determination of the IC50 of
MGC 2 on MDDCs. (D) Viral titers in the
cell-free supernatants of DENV-infected
MDDCs were determined in Vero cells as
FACS infectious units (FIU/ml). For panels
B–D, each symbol represents a diﬀerent
blood donor and the mean values (± SD)
are shown as horizontal bars (****:
p < 0.0001, **: p < 0.01).
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3. Results
3.1. Inhibition of DENV infection of human dermal dendritic cells
The human dermis comprises two dermal dendritic cell (DC) sub-
sets, CD1c+ and CD14+, that are highly permissive to productive in-
fection by DENV and represent an important portal to systemic spread
(Cerny et al., 2014; Schaeﬀer et al., 2015; Schmid et al., 2014).
Therefore, we investigated the anti-DENV eﬃcacy of MGC 2 on human
dermal DCs, a trimannoside linked to a 24-carbon saturated fatty acyl
chain (Fig. 1A). Isolated from normal human skin, the cells were pre-
incubated with IL-4 to increase infectivity (Schaeﬀer et al., 2015) and
then pretreated with MGC 2 for 30min before exposure to DENV-2.
After 2 days, viral infection of the CD1c+ and the CD14+ DC subsets
was assessed by ﬂow cytometry by detection of intracellular DENV-2
envelope protein. 100 μM conjugate potently inhibited DENV-2 infec-
tion of both subsets (Fig. 1B). The analysis of dermal DCs from diﬀerent
donors in the absence or presence of IL-4 showed signiﬁcant reduction
of infection of both DC subsets in all conditions and with both con-
centrations (10 or 100 μM) (Fig. 1C and D). To determine viral progeny,
we exposed Vero cells to the supernatants and determined their infec-
tion by FACS. Although not as accurate as the plaque assay (Lambeth
et al., 2005), the measures showed the reduction of infectious viral
particle release by MGC 2 (Supplemental Fig. S1). Toxicity measures
showed minimal toxicity (CC50= 921 μM ± 112) while the IC50 value
was 1.4 μM ± 0.7 (Table 1). This shows that MGC 2 inhibits productive
DENV infection of skin DCs.
3.2. Inhibition of DENV infection of human monocyte-derived DCs
Following infection of dermal DCs and macrophages, monocytes
that circulate in the blood are recruited to the dermis and diﬀerentiate
into monocyte-derived DCs (MDDCs). Their infection would constitute
a second wave of infection in the skin (Schmid and Harris, 2014). In the
light of this and because MDDCs are more easily obtained than skin
DCs, we repeated the tests on MDDCs with 100 μM of MGC 2. We found
that the conjugate also inhibited DENV infection of these cells (Fig. 2A).
The results obtained with MDDCs derived from monocytes from dif-
ferent blood donors demonstrated signiﬁcant inhibition of productive
infection with 10 μM and 100 μM (Fig. 2B). The IC50 was 1.0 μM ± 0.5
(Fig. 2C) and the CC50 was 1544 μM ± 152 (Table 1). The infectivity of
the cell supernatants titrated on Vero cells conﬁrmed a strongly reduced
production of infectious viral particles (Fig. 2D). Taken together, MGC
2 inhibits productive viral infection of ex vivo or monocyte-derived DCs
with a high selectivity index.
3.3. MGC is active in diﬀerent cell types and against diﬀerent DENV
serotypes
We next veriﬁed whether cell types other than DCs are sensitive to
MGC inhibition. We ﬁrst tested human dermal macrophages. Similar to
CD14+ dermal DCs, IL-4 enhanced their infection, which was inhibited
by MGC 2 at 10 μM and 100 μM concentrations (Fig. 3A). Because after
entry into the skin, DENV spreads systemically and can infect the liver
(Martina et al., 2009), we tested hepatoma cells. The cells were infected
with all four DENV serotypes, and the proportion of infected cells in the
absence of MGC 2 was set to 100% for each serotype for better com-
parison. The results showed a dose-dependent inhibition of infection by
all four serotypes (Fig. 3B), albeit with a slightly higher IC50 value
(Table 1). Finally, given this cell-unspeciﬁc activity, we tested Vero
cells. Also Vero cells were sensitive to MGC 2-mediated DENV inhibi-
tion (Fig. 3C). These ﬁndings demonstrate that MGC 2 displays a similar
inhibition eﬃciency in unrelated cell types susceptible to DENV infec-
tion.
3.4. MGC 2 blocks DENV replication at early steps of infection
Because of its cell-indiscriminate activity, we reasoned that inhibi-
tion of infection by MGC 2 may not be mediated by cell-speciﬁc re-
ceptors. Therefore, to better understand its mode of action, we per-
formed time-of-addition experiments in MDDCs by adding or removing
the inhibitor at diﬀerent time points. Results showed that 10 μM of
MGC 2 abolished viral replication when present throughout (b-d) or
during most (e) of the virus-cell contacts (Fig. 4A). However, infection
was not reduced when MGC 2 was added to the cells and then washed
oﬀ before exposure to the virus (f). This supports the notion that the
conjugate does not stably interact with a viral receptor to block virus
attachment. Infection also occurred when it was added after viral
Fig. 3. Eﬀect of MGC 2 on DENV infection of diﬀerent cell types. Cells were
preincubated with MGC 2 for 30min before exposure to the virus for 2 h. The
percentage of infection was measured after 2 days by FACS as the intracellular
accumulation of DENV-E protein. (A) The graph depicts the percentage of
dermal macrophages positive for DENV-E protein as a function of MGC con-
centrations for each skin donor, either untreated or IL-4-stimulated. Each donor
is represented by a symbol. Mean values (± SD) are shown as horizontal bars.
(B) HepG2 cells were exposed to DENV-1, -2, -3, and -4 serotypes. Histograms
present the mean % of infection (± SD) relative to untreated, DENV-infected
cells (at least 2 experiments in duplicate). (C) DENV-2 infection of Vero cells.
Histograms present the mean values (± SD) of infection and each experiment is
represented by symbol. (*: p < 005; **: p < 0.01 ***; p < 0.001; ****;
p < 0.0001).
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exposure and was not removed (g, h). These ﬁnding showed that the
compound is active only when present during the early viral infection
events.
We next sought to determine whether MGC 2 aﬀects viral inter-
nalization. MDDCs were pretreated or not with the compound for
30min before adding the virus (condition ‘c’ of Fig. 4A). After 1 h, the
cells were washed free of excess virus and inhibitor, and incubated for
another hour before ﬁxing the cells for confocal microscopy (Fig. 4B).
The cells were labeled with an anti-DENV-speciﬁc ﬂuorescent antibody
and with ﬂuorescent dyes to visualize cell membrane and nucleus. As
expected for a successful infection, the number of virions was higher
within the cell than at the membrane; however, strikingly, this number
was not signiﬁcantly changed by the compound. These ﬁndings showed
that MGC 2 prevented neither attachment nor internalization of DENV
particles. It was notable that the distribution of the lipophilic mem-
brane dye was diﬀerent between the untreated and treated cells.
Given that the exit of the DENV RNA from endosomes into the cell
cytoplasm requires low pH (Modis et al., 2004), we next asked whether
endosomal pH is aﬀected by MGC 2. Vero cells were treated with 10 μM
or 100 μM of the compound or with inhibitors of endosomal acidiﬁca-
tion. After 0.5 h or 3 h, the cells were incubated with LysoSensor Green
whose ﬂuorescence is sensitive to pH (Fig. 4C and Supplemental Fig.
S2). As expected, whilst NH4Cl and baﬁlomycin A1 decreased the
ﬂuorescence intensity, reﬂecting a block in endosomal acidiﬁcation,
MGC 2 caused no signiﬁcant change irrespective of time of exposure or
concentration. Taken together, the data show that MGC 2 inhibits an
event between viral uptake into endosomes and nucleic acid exit into
the cytoplasm, but that does not imply an interference with endosomal
acidiﬁcation.
Fig. 4. MGC 2 aﬀects early steps of the DENV replication cycle. (A) Schematic representation of time-of-addition experiments with MDDCs using MGC 2 (10 μM)
and DENV-2 virus (MOI of 0.2). The graph shows the percentage of infection (± SD, 3–5 blood donors) measured after 48 h by intracellular accumulation of DENV-E
protein, relative to untreated cells (condition ‘a’). (B) Assessment of viral particles in MDDCs, untreated or treated with MGC 2 as indicated in the scheme. DENV, cell
membrane and nucleus were identiﬁed using Cy3-conjugated mAb 4G2 (red), DiD (green) and DAPI (blue), respectively. The graph depicts the mean number of
virions (± SD, 3 blood donors) on the membrane and in the cytoplasm. (C) Eﬀect of MGC 2 on the endosomal pH. Vero cells were left untreated or treated with the
inhibitors of endosomal acidiﬁcation NH4Cl and baﬁlomycin A1 for 3 h, or with MGC (100 μM) for 0.5 h or for 3 h. LysoSensor Green DND-189 was added for
4 min at 37 °C before ﬂow cytometry analysis. Results show the mean ﬂuorescence intensity (MFI, SD, 3 experiments) of LysoSensor Green relative to that of
untreated cells. (**: p < 0.01; ***: p < 0.001; ****: p < 0.0001).
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3.5. Structure-activity relationship studies: importance of the lipid chain
To further clarify the molecular mechanism of MGC 2 antiviral ac-
tivity, improve antiviral activity and also to obtain a ﬂuorescent deri-
vative, we altered the sugar and lipid moieties of MGC 2. Inhibition of
DENV-2 infection of MDDCs was completely lost in the absence of the
sugar head (NHPD), yet replacing mannose by galactose (MGC 9) or
sialic acid (MGC 10) had little impact (Fig. 5A and Supplemental Fig.
S3). We designed diﬀerent MGCs with variations in their lipid moiety to
modulate their rigidity or ﬂexibility (Fig. 5B). The absence of a lipid
moiety (MGC 1) abolished activity. MGC 3 and 4 containing a short
(19–21 carbons) polyunsaturated fatty acid chain were also inactive.
Similarly, alteration of a short carbon chain with a benzene group in
MGC 5 or a ﬂuorescent NBD group in MGC 11 abolished activity. Only a
minor modiﬁcation introduced in the 24-carbon saturated chain of
MGC 2 by replacing two saturated bonds with two unsaturations of
linear geometry (MGC 2U) marginally reduced antiviral activity
(Fig. 5B and Supplemental Fig. S3). These ﬁndings show that the sugar
head is exchangeable, but that the lipid moiety cannot accommodate
major modiﬁcations of the C24 saturated fatty acyl chain of MGC 2.
3.6. Cell membrane polarization by MGCs correlates with antiviral activity
We had previously found that MGC 2 and 2U negatively aﬀected
LPS signaling in MDDCs and altered the cell membrane distribution of
the signaling receptors (Flacher et al., 2015). In addition, we have
noted the eﬀect of MGC 2 on the distribution of lipid dye DiD (Fig. 4B).
Because lipid chain length and chemical composition are likely to aﬀect
the aﬃnity of MGCs for the cell membrane, we asked whether there was
a correlation between the ability to insert into the cell membrane and
the antiviral activity. Since a ﬂuorescently tagged analog of MGC 2
(MGC 11) was inactive, we addressed this question indirectly by
monitoring the cell membrane distribution of the strongly ﬂuorescent
membrane dye dSQ12S (Collot et al., 2015). We compared untreated
THP-1 cells with cells exposed to MGC 2, MGC 2U (slightly decreased
antiviral activity) and MGC 1 (no antiviral activity). The cell
Fig. 5. Eﬀect of sugar head and lipid chain variations of MGC 2 on DENV infection. (A) Left panel, structure of conjugates containing sugar variations (9, 10,
with galactose or sialic acid) instead of mannose, or without a sugar moiety (NHPD). Right panel, MDDCs were either untreated of treated with MGC 2 or with the
indicated variations of MGC 2 (concentrations of 10 and 100 μM) for 30min before exposure to DENV-2 (MOI of 0.2). The percentage of infection was measured by
intracellular accumulation of DENV-E protein and expressed as the proportion relative to the untreated control. Data are the mean ± SD of triplicates and are
representative of 3 diﬀerent donors. (B) Left panel, structures of conjugates containing lipid variations (1 contains no lipid chain, 2U contains an unsaturated C24
lipid chain, 3, 4 have an omega-3 and omega-6 lipid chain, conjugate 5 has a benzene-ending lipid chain, conjugate 11 contains a ﬂuorescent NBD motif). All
compounds, except 11, were previously described (Dehuyser et al., 2012; Schaeﬀer et al., 2013; Flacher et al., 2015). Right panel, as for panel A, only that the lipid
chain was either lacking (MGC 1) or variations were introduced (MGC 2U, 3, 4, 5, 11). *: p < 0.05; **: p < 0.01; ***: p < 0.001 ****: p < 0.0001.
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ﬂuorescence was visualized and evaluated using imaging ﬂow cyto-
metry to detect slight alterations in cell membrane ﬂuorescence pat-
terns (Marangon et al., 2013; Zuba-Surma et al., 2007). In untreated
control cells there was a homogeneous distribution of the plasma
membrane dye (population R1), however 39% of the cells treated with
MGC 2 displayed a polarized dye localization (population R2) (Fig. 6A
and B). Strikingly, the proportion of the cells with membrane dye po-
larization was only 24.6% with MGC 2U and 4% with MGC 1. These
ﬁndings show that the presence of the lipid and its nature disrupt the
even distribution of the cell membrane dye, and the degree of dis-
turbance correlates with the antiviral activity of the MGCs.
4. Discussion
In this study we showed that MGC 2 inhibits the productive infec-
tion of diﬀerent cell types by DENV. The compound does not inhibit
viral cell-entry, and the endosomes acidify normally. However, it per-
turbs the cell membrane, which most likely aﬀects subsequent viral
membrane-endosome fusion leading to blockage of viral genome entry
into the cytoplasm.
We had previously shown that dermal CD14+ DCs were highly
susceptible to DENV infection that was further increased by IL-4
(Schaeﬀer et al., 2015). We found that even in the presence of IL-4,
MGC 2 inhibited the infection of dermal DCs in the low μM range.
Activity on DCs was conﬁrmed with MDDCs. Because DCs express DC-
SIGN that enhances DENV infection by binding the glycosylated viral
envelope protein (Navarro-Sanchez et al., 2003; Tassaneetrithep et al.,
2003), we ﬁrst suspected interference of the mannosylated conjugates
with DC-SIGN for binding the virus. Indeed, MGC 2 has aﬃnity for
recombinant DC-SIGN (Schaeﬀer et al., 2013). The lipid chain plays an
important role in the aﬃnity of MGCs to recombinant DC-SIGN
(Dehuyser et al., 2012), which is most likely related to the formation of
micelles and hence an increase in avidity. However, the ﬁnding that
MGC 2 displays antiviral activity in hepatoma and Vero cells that lack
this lectin, shows that the MGC 2 activity is not solely explained by a
competition with the virus for DC-SIGN. Further, while the replacement
of the mannose by a diﬀerent sugar abolished interaction to DC-SIGN
(Schaeﬀer et al., 2013), it had little impact on anti-DENV activity. On
the other hand, we found that the lipid chain plays a critical role in the
antiviral activity. How to consolidate these ﬁndings? All things con-
sidered, we interpret the data that MGCs in their micellar form bind
with high aﬃnity to any cell surface lectins; once bound, the micelles
are disrupted to allow the lipid chain to insert into the membrane lipid
bilayer. Owing to this dual function, namely formation of micelles and
entry into the cell membrane, modiﬁcations of the lipid chain are
poorly tolerated. In addition, the diﬀerent fatty acids are likely to have
an impact on cell membrane composition and physical properties. The
polyunsaturated fatty acids (in MGC 3, 5) would have a favorable in-
teraction with the non-raft membrane domains, resulting in the stabi-
lization of the ordered rafts (Levental et al., 2016), whereas the satu-
rated MGC 2 is likely to assemble into the ordered, saturated lipid-raft
membrane domain and induces its destabilization (Sezgin et al., 2017).
The more rigid MGC 2U with two triple unsaturations would be less
tightly associated with the lipid raft. On this basis, MGC antiviral action
would correlate with raft incorporation and destabilization.
Although our data cannot exclude a direct interaction of MGC 2
Fig. 6. MGCs aﬀect lipid dye distribution in the plasma membrane. Amnis ImageStreamX ﬂow cytometry analysis after incubation of THP1 cells with the
lipophilic ﬂuorescent dye dSQ12S (100 nM) for 10min, before addition of MGCs (100 μM) for 10min. (A) Representative images of cells of the R1 and R2 cell
population. Columns on the left: brightﬁeld; middle columns: red ﬂuorescence of the probe, showing probe capping in R2 cells; columns on the right show brightﬁeld
merged with the ﬂuorescence images. (B) Delta centroid cell polarity analysis showing the frequency of cells in the diﬀerent conditions with uniform membrane dye
staining (R1 population) and with a capped membrane distribution (R2 population). The proportion of the R2 population is indicated (representative of two
experiments).
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with the DENV envelope, they clearly point to a cell membrane al-
teration resulting in a subsequent block of virus fusion out of endo-
somes. Further work is required to determine in what way MGC 2 could
alter the lipid/protein composition or the dynamics (stiﬀness versus
ﬂuidity) of the membranes.
The role of lipids in viral infection (entry, traﬃcking, replication
and egress) is well recognized (Mazzon and Mercer, 2014); in the case
of DENV, this virus utilizes a speciﬁc lipid for fusion from the late en-
dosomes (Zaitseva et al., 2010). Thus, the pharmaceutical interference
of cellular membrane composition and ﬂuidity represents a new para-
digm for broad-spectrum antiviral discovery (Pollock et al., 2010; St
Vincent et al., 2010; Vigant et al., 2015). In addition to exploring the
molecular interaction between MGCs and cell membrane lipids, a fur-
ther question is whether MGC 2 confers protection against viruses other
than DENV, given the broad-spectrum antiviral activity that results
from targeting membranes. The high selectivity index of MGC 2 in
human cells and its good water solubility makes this conjugate a novel
and attractive candidate for further testing in cellular and animal
models.
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